Xavier Calvet, MD, PhD; Albert Villoria, MD; Mercedes Vergara, MD, PhD
Potential Financial Conflicts of Interest: None disclosed.
Calvet X, Villoria A, Vergara M. Could Increasing the Duration of Triple Therapy Be a Clinically Useful Strategy?. Ann Intern Med. 2008;148:624. doi: 10.7326/0003-4819-148-8-200804150-00009
Download citation file:
Published: Ann Intern Med. 2008;148(8):624.
TO THE EDITOR:
We would like to congratulate Fuccio and colleagues (1) on their well-performed meta-analysis comparing different durations of triple therapy for Helicobacter pylori infection. However, we disagree with their conclusion that prolonging treatment is unlikely to be a clinically useful strategy. In our opinion, this statement is not supported by their results. The authors confirm previous findings (2, 3) that extending duration of treatment from 7 days to 10 or 14 days improves eradication rates, although the improvements in eradication rates (4% for 10 days and 5% for 14 days) were slightly lower than those previously reported (3% for 7 days, 8% for 10 days, and 12% for 14 days) (2, 3). They also found that extending treatment from 7 to 10 days increases efficacy in patients with nonulcer dyspepsia (relative risk difference, 11%) but not in patients with ulcer (relative risk difference, 2%) (4).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only